Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotagliflozin - Lexicon Pharmaceuticals

Next Previous
Drug Profile

Sotagliflozin - Lexicon Pharmaceuticals

Alternative Names: INPEFA; LP-802034; LX-4211; SAR 439954; Zynquista

Latest Information Update: 13 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Lexicon Pharmaceuticals; Sanofi; Viatris Inc
  • Class Alcohols; Antihyperglycaemics; Cardiovascular therapies; Chlorobenzenes; Glycosides; Heart failure therapies; Phenyl ethers; Pyrans; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Type 2 diabetes mellitus
  • Registered Type 1 diabetes mellitus
  • Phase III Hypertrophic cardiomyopathy

Most Recent Events

  • 13 Aug 2026 Preregistration for Heart failure in Singapore, Oman, Thailand, Turkey, Malaysia, Philippines, Kuwait (PO) prior to August 2026
  • 13 Aug 2026 Registered for Heart failure in Bahrain (PO) prior to August 2026
  • 06 Aug 2026 Viatris anticipates regulatory decisions in Australia and Canada in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top